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With stringent U.S. federal restrictions on funding for human embryonic stem cell research 
still in place, states grapple with the issue of whether to fund such research themselves.When California voters approved spend-
ing state money for human embryonic 
stem (ES) cell research last November, 
other states began to formulate their 
own funding plans. However, court bat-
tles in California and political machina-
tions elsewhere have slowed efforts by 
the states to circumvent federal restric-
tions on such research.
Since 2001, the use of U.S. federal 
dollars for research on human ES cells 
has been restricted. Scientists can only 
use about two dozen human ES cell lines 
for research funded with federal dollars, 
which has hampered progress. Work 
prohibited by the federal policy can con-
tinue with private funds, but researchers 
with private support have had to keep 
these projects separate from any work 
bankrolled by federal dollars.
To address the shortfall in federal 
cash for human ES cell research, a 
number of U.S. states are looking at 
ways to raise funds to support such 
studies, and California is leading the 
way. Last November, 59% of California 
voters approved Proposition 71 to cre-
ate the California Institute for Regen-
erative Medicine (CIRM). This institute 
aims to provide $3 billion in state-
issued bonds over 10 years for human 
ES cell research. The strategy is that 
investors would purchase the bonds, 
providing money for the research, and 
in return would receive interest pay-
ments on their investment. But a series 
of lawsuits have stalled the issuing of 
bonds and the dispersal of funds. One 
lawsuit argues that the Independent 
Citizens Oversight Committee—which 
presides over CIRM—is not under 
state control, and thus cannot handle 
state-issued bonds. Another lawsuit 
contends that committee members 
may have a conflict of interest because 
they work for California universities or 
companies that could reap the benefits of the funding initiative. Although the 
lawsuits address procedural issues, 
they are backed by the California Fam-
ily Bioethics Council and the Life Legal 
Defense Foundation, groups opposed 
on ethical grounds to ES cell research. 
CIRM overcame one hurdle last month 
when a California judge ruled against 
a request to nullify parts of Proposi-
tion 71, saying that the plaintiffs in the 
lawsuits had not yet demonstrated 
that the institute violates California’s 
state constitution. However, the judge 
did not dismiss the case, which will 
go to trial in February. The case could 
remain hung up in courts well into next 
year, which leaves the funding of CIRM 
in doubt.
These setbacks “haven’t taken 
momentum out of the interest in stem 
cell research,” says David Peckman, 
associate director of the Institute for 
Stem Cell Biology and Medicine at 
University of California, Los Angeles. 
“It’s of some concern, but it’s a politi-
cal issue that will be resolved,” he says. 
Daniel Perry, president of the Coali-
tion for the Advancement of Medical 
Research in Washington D.C., agrees: 
“It’s a delay but it will not be fatal.” In 
the meantime, CIRM has subsisted 
on emergency funding, including a $3 
million loan from the state, and a $5 
million donation from the foundation of 
inventor Ray Dolby, which will keep the 
institute staffed and running through 
Spring 2006. In a tentative step for-
ward, the CIRM awarded its first set of 
grants in September this year, allocat-
ing $12.5 million for training graduate 
students, postdoctoral fellows, and 
clinical researchers at 16 institutions 
in California. No one knows when the 
institutions will receive the money, but 
CIRM says that it will provide funding 
through so-called bond anticipation 
notes, a stopgap financing measure Cell 123, Decethat circumvents the need to issue 
state bonds.
The promise of a windfall for stem 
cell research funding has attracted 
some researchers to California. For 
instance, Stefan Heller, who studies 
stem cells of the inner ear, left a fac-
ulty position at Harvard and moved 
to Stanford this fall. Proposition 71 
helped to entice him. “It played a role 
for sure,” he says. Heller has been 
surprised by how few of his scientific 
colleagues have seriously considered 
moving to California, a fact that he 
attributes to a lack of interest in leav-
ing communities where researchers 
have established personal roots. Still, 
the potential for state research money 
“was certainly not a decisive issue for 
me,” says Heller. Just as important 
were opportunities for collaboration 
at Stanford; teaming up with other 
researchers was possible at Harvard, 
he says, but it was difficult with labs 
spread throughout Boston. “Stanford 
offers everything in one place,” he 
says. And despite federal restrictions 
on funding for human ES cell research, 
Heller points out that researchers can 
find alternative sources of funding for 
solid research projects.
A stimulating research environment 
prompted another stem cell researcher 
to move in the opposite direction and 
leave California. Meri Firpo, now at the 
University of Minnesota, left her previ-
ous post as a research professor at the 
University of California, San Francisco, 
in April. “I did not contemplate staying” 
because of the initiative, she says. “I 
chose based on the research environ-
ment I was moving into.” She points 
out that the availability of experts on 
pancreatic islet transplantation at the 
University of Minnesota should facili-
tate moving her research on devel-
oping stem cell-based therapies for mber 29, 2005 ©2005 Elsevier Inc. 1169
diabetes into clinical studies. “Fund-
ing is an important aspect but it’s 
really only one point,” she says. And 
in retrospect, “if I had chosen to stay 
in California, that would have been a 
mistake” because of the delay in dis-
persing research money by CIRM.
Other researchers have moved too, 
but not to California. In late November, 
Neal Copeland and Nancy Jenkins, 
cancer researchers at the National 
Cancer Institute in Frederick, Mary-
land, announced that they would move 
their laboratories to Singapore. Heavy 
investment in biotechnology and more 
permissive policies toward stem cell 
research have enabled Singapore to 
become a scientific mecca for many 
researchers including those who work 
on stem cells. New advances in stem 
cell research could aid Copeland and 
Jenkins in their efforts to study genetic 
changes leading to cancer. Stanford 
University had been wooing the pair, 
who cited restrictions on research and 
delays in Proposition 71 funding as fig-
uring heavily in their decision.
In addition to Singapore, other 
countries are poised to forge ahead as 
federal restrictions hamper research-
ers in the United States. Researchers 
in South Korea led by Woo Suk Hwang 
have marked significant milestones in 
therapeutic cloning research, creat-
ing cloned human embryos, nurtur-
ing stem cell lines from patients with 
particular diseases, and devising more 
efficient methods for cloning embryos. 
In October, Hwang announced the 
formation of a World Stem Cell bank, 
which would provide scientists world-
wide with human ES cell lines. The 
Korean efforts have been tarnished, 
however, by Hwang’s recent admission 
that egg donors had been paid and 
that the team’s own scientists donated 
eggs for some studies, raising ethi-
cal concerns. Hwang had previously 
denied both allegations. Hwang sub-
sequently resigned as director of the 
World Stem Cell Bank, and one of his 
associates has taken the helm. And 
some researchers are now questioning 
the scientific validity of the team’s June 
2005 Science paper because a figure 
showing DNA fingerprinting matches 
between human ES cell lines and the 
patients from which they were derived 1170 Cell 123, December 29, 2005 ©2005seems to contain duplicate traces. It 
has yet to be established whether the 
irregularity arose from a publication 
error or from scientific fraud. 
If California’s funding effort bears 
fruit, it could help researchers in Cali-
fornia to keep pace with research 
advances outside the United States. 
And the threat of a new California gold 
rush has inspired researchers and 
politicians in other states to follow suit. 
“There was concern that there would 
be a giant sucking sound from Cali-
fornia slurping up researchers,” says 
David Beck, CEO of the Coriell Insti-
tute for Medical Research in Camden, 
New Jersey, and a member of the New 
Jersey Commission on Science and 
Technology. The state of New Jersey 
allocated $11.5 million in May 2004 
to start the Stem Cell Institute of New 
Jersey. The research committee of the 
state commission is currently review-
ing applications for $5 million dollars 
in state research funding, says Beck, 
the committee’s chair. “We want to 
be the first state to put money out on 
the street,” he says. Acting Governor 
of New Jersey Richard Codey also 
announced plans this year to devote 
$150 million in state funds to provide a 
building for the institute. (Jon Corzine 
was elected governor by New Jersey 
voters in November; Codey did not 
run.) In addition, Codey introduced 
a bill into the New Jersey legislature 
this year to authorize $230 million in 
state-issued bonds to fund stem cell 
research, including work on human ES 
cells. Wrangling over this and a simi-
lar but competing bill prevented pas-
sage in time to put a bond measure 
before New Jersey voters this Novem-
ber. Research advocates aim to have 
a measure on the ballot next fall. To 
avoid any concerns about conflicts 
of interest, the research commission 
is aiming to keep grant review com-
mittees as independent as possible, 
he says. And “we’re aiming to keep a 
low profile” to avoid the intense media 
exposure surrounding Proposition 71, 
says Beck.
The state of Connecticut is also 
moving into the stem cell research 
arena. In January 2005, Governor 
Jody Rell advocated spending $20 
million of the state’s budget surplus to  Elsevier Inc.fund human stem cell research. And in 
July, lawmakers approved legislation 
allowing all forms of stem cell research 
in the state, and appropriated $10 mil-
lion over 10 years to support the work. 
The law forbids reproductive cloning 
but allows therapeutic cloning. Blood 
stem cell expert Diane Krause of 
Yale University in New Haven is opti-
mistic the move will attract stem cell 
researchers to Connecticut. Yale Uni-
versity recently attempted to woo two 
stem cell researchers, who instead 
took positions in California, Krause 
says. Losing top people “is certainly 
one of our concerns.”
In other states, research advo-
cates have met fierce opposition to 
state-supported stem cell research. 
The Missouri legislature has consid-
ered several bills that would outlaw 
therapeutic cloning. “That persistent 
attempt has created an uncertainty 
that has interrupted expansion of 
the Stowers Institute,” says William 
Neaves, director of the Kansas City, 
Missouri, nonprofit research organiza-
tion, “and have stymied attempts to 
recruit promising young scientists.” To 
counter the push to ban therapeutic 
cloning in Missouri, a coalition of advo-
cates launched a campaign in October 
to put a constitutional amendment on 
next November’s ballot; approval by 
voters would permit therapeutic clon-
ing and prevent any bans on using this 
approach. The initiative won’t provide 
any research dollars, says Neaves. 
“No one expects the state taxpayers to 
provide funding,” but he says that the 
amendment would help to ensure that 
Missouri is “a very cordial environment 
for biomedical research.”
Other states have also launched 
stem cell efforts. In Illinois, Gover-
nor Rod R. Blagojevich issued an 
executive order in July this year that 
allocated $10 million for stem cell 
research and the creation of the Illi-
nois Regenerative Medicine Institute. 
Blagojevich even sent letters to Mis-
souri stem cell researchers in August 
inviting them to relocate to Illinois. In 
October, Governor Robert Ehrlich, Jr., 
of Maryland promised that his agenda 
for next year would include a stem cell 
program, after conservative state leg-
islators killed a $25 million bill for stem 
cell research in April. This fall, research 
advocates in Florida launched an 
effort to put a $200 million stem cell 
research initiative on the November 
2006 ballot. In other states, research 
proponents posted more modest vic-
tories. In November, Wisconsin Gover-
nor Jim Doyle vetoed a bill that would 
outlaw therapeutic cloning to create 
stem cell lines. Texas advocates also 
fended off legislation that would outlaw 
some forms of stem cell research; the 
Texas House signed off on a bill that 
would allocate $41.1 million dollars to 
establish a stem cell research institute. 
Virginia lawmakers passed a bill that 
would allow ES cell research, but later 
struck provisions to fund the work with 
state money. Meanwhile, the New York 
and Pennsylvania legislatures intro-
duced bills this year that would permit 
ES cell research and would provide 
state funding.
State funds for stem cell research 
will likely come in a trickle rather than a 
flood, but some experts say that private 
money is sufficient to move the field 
forward regardless of what happens 
with state and federal funding. “We do 
of course hope that the NIH will even-
tually be able to support all kinds of 
stem cell research,” says Neaves. “But 
the federal ban has not really affected 
us. We have sufficient internal funding 
to enable our scientists to undertake 
any research they wish.” Other institu-tions are reaping the rewards of pri-
vate funding. The Harvard Stem Cell 
Institute in Cambridge, Massachu-
setts operates primarily on gifts from 
private donors. And in May, the Starr 
Foundation announced a $50 million 
dollar contribution for human stem cell 
research (including ES cell studies) to 
three New York City institutions: Rock-
efeller University, Memorial Sloan-Ket-
tering Cancer Center, and Weill Medi-
cal College of Cornell University.
As states continue to explore ways 
to support stem cell research, there are 
inklings that federal restrictions might 
be loosened. In May, the United States 
House of Representatives passed a 
bill that would broaden federal fund-
ing for stem cell research, allowing the 
derivation of new stem cell lines from 
human embryos created by in vitro 
fertilization. In July, Senate Majority 
Leader Bill Frist broke with President 
George Bush and announced his sup-
port for the bill. The Senate would vote 
on the bill in 2005, Frist said. But other 
business—such as disaster relief and 
Supreme Court justice hearings—has 
halted discussion of the Senate stem 
cell bill. Senator Arlen Specter of Penn-
sylvania, the bill’s sponsor, threatened 
to put the brakes on a mandatory 
spending bill until the stem cell issue 
was decided but has now relented in 
return for Frist’s promise of consider-
ing the stem cell bill early in 2006. Nei-Cell 123, Decether house has enough votes to over-
ride a presidential veto, however.
Regardless of what transpires in 
individual states, a change in direction 
at the federal level is vital for the field, 
say many researchers. “I do not feel 
that this is or should be a state issue,” 
said Harvard Stem Cell Institute codi-
rector Douglas Melton in an email. 
Embryonic stem cell research should 
be part of a progressive national 
health care policy, and segregating 
research efforts doesn’t encourage 
cooperation, he added. The federal 
restrictions force scientists to pursue 
research avenues solely to conform 
to politics, says Peter Mombaerts of 
the Rockefeller University in New York 
City, who studies methods for gen-
erating stem cell lines through thera-
peutic cloning in mice. For instance, 
in October of this year, two teams 
reported methods for generating 
human ES cell lines without harming 
a viable human embryo. “If there were 
not these restrictions, I would not do 
this research,” says Harvard Univer-
sity stem cell scientist Rudolf Jae-
nisch, who led one of the groups. As 
state officials move to resolve prob-
lems over funding for human ES cell 
research, scientists keep their sights 
on the ultimate goal: a better under-
standing of stem cell biology and the 
possibility of therapeutic applications 
of stem cell research.
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